Prescribing Ivermectin Off-Label: A State-by-State Look at Where Physicians Stand on Firm Legal Ground

A physician practicing in Tennessee operates under a fundamentally different regulatory environment than one licensed in New York — not merely in terms of administrative procedure, but in terms of the actual legal risk associated with prescribing ivermectin for indications beyond those listed on the FDA-approved label. This divergence is not accidental. It reflects deliberate policy choices made at the state level, and it has produced a patchwork of protections and prohibitions that directly determines whether patients in a given jurisdiction can access ivermectin through conventional medical channels.

Understanding this landscape requires familiarity with how medical boards operate, what authority they hold, and how they have chosen to exercise that authority in the specific context of ivermectin off-label prescribing.

How Medical Boards Govern Prescribing Practice

Medical boards in the United States are state-level regulatory bodies charged with licensing physicians and disciplining those who violate professional standards. They do not set clinical treatment protocols — that function belongs to professional medical societies and specialty organizations — but they do define the boundaries of acceptable practice within their jurisdictions, and they possess the authority to impose sanctions ranging from formal reprimand to license revocation.

Off-label prescribing — the practice of recommending an FDA-approved drug for an indication, dosage, or population not specified in its labeling — is legal under federal law. The FDA explicitly acknowledges that physicians may exercise clinical judgment in this manner. However, federal permissibility does not insulate a prescriber from state-level discipline if a medical board determines that the prescribing pattern fell below the applicable standard of care.

This distinction is crucial. The question is not whether off-label prescribing is legal in the abstract, but whether a specific board will characterize a specific prescribing decision as professionally appropriate.

States That Have Enacted Explicit Protections

A meaningful cluster of states has moved affirmatively to protect physicians who prescribe ivermectin — and in some cases other contested medications — from medical board discipline. These protections typically take one of two forms: legislative action or board-issued guidance that explicitly recognizes off-label prescribing as within the standard of care.

Tennessee enacted legislation in 2023 that restricts the Tennessee Board of Medical Examiners from disciplining physicians solely on the basis of prescribing FDA-approved medications for off-label purposes, provided the physician exercises reasonable clinical judgment and obtains informed consent. This law was widely understood as a direct response to the ivermectin prescribing controversy.

Iowa passed similar legislation creating a safe harbor for off-label prescribing, with the explicit acknowledgment that clinical evidence and patient-physician conversation should govern prescribing decisions rather than regulatory presumption.

Nebraska and Kansas have adopted board-level guidance affirming that off-label prescribing, standing alone, does not constitute unprofessional conduct — language that provides meaningful if not absolute protection for physicians who can document a rational clinical basis for their decisions.

Texas presents a more complex picture. The Texas Medical Board has not enacted blanket protections, but the state's legislature has been active in limiting board authority in related areas, and the board's enforcement record on ivermectin specifically has been relatively restrained compared to jurisdictions with more assertive regulatory postures.

States Where Prescribers Face Greater Exposure

At the other end of the spectrum, several states have taken positions — through formal board guidance, public statements, or enforcement actions — that signal heightened scrutiny of ivermectin prescribing.

New York has been among the more aggressive jurisdictions. The New York State Department of Health issued guidance during the pandemic explicitly cautioning pharmacists against dispensing ivermectin for COVID-19 without verification of an approved indication, and the state's Board for Professional Medical Conduct has investigated prescribers who operated outside mainstream clinical consensus.

California issued guidance through the Medical Board of California emphasizing that prescribing ivermectin for COVID-19 without a legitimate medical basis could constitute unprofessional conduct. Assembly Bill 2098, passed in 2022, attempted to codify this position by characterizing COVID-19 misinformation — a category that regulators could apply to ivermectin advocacy — as grounds for discipline. That law was subsequently repealed in 2023 following significant physician pushback and constitutional concerns, but the underlying regulatory posture remains cautious.

Oregon and Washington have maintained relatively strict regulatory environments, with board communications emphasizing adherence to evidence-based guidelines issued by mainstream professional organizations.

The Gray Zone: States Without Clear Guidance

The majority of states occupy an intermediate position — neither explicitly protecting off-label ivermectin prescribers nor actively pursuing them. In these jurisdictions, the operative standard is typically the general professional conduct framework, which evaluates prescribing decisions based on whether a reasonable physician in similar circumstances would have made the same choice.

This ambiguity is not necessarily benign. Without clear guidance, physicians in these states must make prescribing decisions under conditions of legal uncertainty, which predictably produces caution. Prescribers who might otherwise be willing to explore ivermectin as a therapeutic option may decline to do so when the professional consequences are difficult to predict.

For patients, this translates directly into access barriers. A physician who cannot assess their own legal exposure with confidence is less likely to prescribe a contested medication — regardless of their private clinical assessment of its merits.

What These Variations Mean for Patient Access Across State Lines

The geographic fragmentation of ivermectin prescribing protections has practical consequences for American patients that extend beyond mere inconvenience. Telemedicine — which has expanded substantially since the pandemic — has partially mitigated these disparities by allowing patients to consult prescribers licensed in more permissive jurisdictions. However, interstate prescribing rules are themselves complex, and not all telemedicine platforms are willing to navigate the regulatory variation involved.

Patients who reside in states with restrictive prescribing environments and who seek ivermectin through telehealth services should verify that the prescribing physician holds a license valid in the patient's home state, and that the platform has assessed the relevant interstate compact rules and board guidance. Prescriptions issued in technical violation of these requirements may be declined by pharmacies and could expose both patient and prescriber to complications.

The Evolving Legislative Landscape

The policy environment surrounding ivermectin prescribing continues to develop. Legislative sessions in multiple states have considered — and in some cases passed — bills addressing off-label prescribing authority, pharmacist dispensing discretion, and medical board enforcement standards. Patients and physicians alike would benefit from monitoring developments in their specific states through official board websites and legislative tracking resources.

The fundamental tension underlying this entire landscape — between physician autonomy and regulatory oversight, between patient access and safety standards — is unlikely to resolve quickly. What is clear is that geography now functions as a meaningful variable in determining whether an American patient can obtain ivermectin through a conventional medical channel, and that understanding the rules in one's own state is an essential first step toward navigating the system effectively.